We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Serum Protein Biomarkers Detect Invasive Breast Cancer

By LabMedica International staff writers
Posted on 01 Oct 2014
The ability of serum protein biomarkers in conjunction with autoantibodies to distinguish between invasive breast cancer and benign breast conditions has been demonstrated.

It has been estimated that 233,000 women will be diagnosed with breast cancer in the USA in 2014 and approximately 40,000 deaths occur from breast cancer each year. More...
While biomarkers are often used to augment detection of various cancers, definitive biomarkers for breast cancer have remained elusive.

Data is now available from a study that measured serum protein biomarkers (SPBs) known to be associated with breast cancer in over 163 serum samples from women with either breast cancer or benign breast conditions. In addition, 28 autoantibodies (AAbs) associated with cancer were analyzed in 31 of these patients. The study demonstrated that the addition of AAbs to a panel of SPBs greatly increases accuracy and using SPBs to distinguish benign from invasive breast cancer yields reasonable but non-clinically meaningful results in menopausal women.

Provista Diagnostics, Inc., (Scottsdale, AZ, USA) is a privately-held molecular diagnostics company focused on developing and commercializing proprietary blood-based diagnostic, prognostic and monitoring tests for cancers affecting women, that announced the data highlighting Provista's proteomic diagnostic that measures multiple breast cancer-specific biomarker proteins in blood samples.

David Reese, PhD, president and CEO of Provista, said, “The presentation of this proof-of-concept data is a major milestone for Provista as we continue to advance the development of our robust pipeline to detect breast and gynecologic cancers in women. Accurate clinical diagnosis of breast cancer depends on the effective use of complementary technologies in conjunction with standard of care, such as imaging. We believe our proteomics approach, which combines the sensitivity of autoantibodies with the specificity of known serum protein biomarkers along with standard-of-care imaging, may reduce the number of missed actionable breast cancers while avoiding the stress and added diagnostic costs of false negative reports.” The study was presented at The American Society of Clinical Oncology's 2014 Breast Cancer Symposium (ASCO-Breast 2014) that took place from September 4-6, 2014, in San Francisco (CA, USA).

Related Links:
Provista Diagnostics


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.